Filter Results:
(313)
Show Results For
- All HBS Web
(1,339)
- Faculty Publications (313)
Show Results For
- All HBS Web
(1,339)
- Faculty Publications (313)
- September 2019
- Case
Dementia Discovery Fund
By: Richard G. Hamermesh, Kathy Giusti and Sarah Gulick
The case is set in March 2019, and tells the story of the founding of the Dementia Discovery Fund (DDF). The idea for the fund began in 2015, when then-Prime Minister David Cameron spoke about the importance of making breakthroughs in dementia research, and pledged... View Details
Keywords: Venture Capital; Investment Funds; Mission and Purpose; Recruitment; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Boston; Massachusetts; London; England
Hamermesh, Richard G., Kathy Giusti, and Sarah Gulick. "Dementia Discovery Fund." Harvard Business School Case 820-045, September 2019.
- 2019
- Article
Pay-for-Monopoly?: An Assessment of Reverse Payment Deals by Pharmaceutical Companies
By: Sana Rafiq and Max Bazerman
Abstract
Over the past eighteen years, pharmaceutical firms have developed a blueprint to impede competition in order
to maintain their monopoly profits. This scheme, termed pay-for-delay, involves direct or indirect payment of
money from a branded-drug manufacturer... View Details
Rafiq, Sana, and Max Bazerman. "Pay-for-Monopoly? An Assessment of Reverse Payment Deals by Pharmaceutical Companies." Journal of Behavioral Economics for Policy 3, no. 1 (2019): 37–43.
- April 2019 (Revised February 2025)
- Case
Wendell Weeks at Corning Inc.: Extending a History of Life-Changing Innovations (A)
By: Ryan Raffaelli, David G. Fubini and Aldo Sesia
This case examines the leadership challenges associated with maintaining a culture of innovation in established organizations. It asks students to step into the shoes of a leader faced with making several tough decisions about when to invest (or to stop investing) in... View Details
Keywords: Innovation and Invention; Organizational Culture; Innovation Leadership; History; Technological Innovation; Investment; Decision Making
Raffaelli, Ryan, David G. Fubini, and Aldo Sesia. "Wendell Weeks at Corning Inc.: Extending a History of Life-Changing Innovations (A)." Harvard Business School Case 419-003, April 2019. (Revised February 2025.)
- April 2019 (Revised January 2025)
- Case
Clear Link Technologies, LLC: Driving Sales with Peer Effects
By: Christopher Stanton, Richard Saouma and Olivia Hull
The importance of a good peer or coworker is widely discussed, but understanding the glue that makes coworkers valuable is less understood. This case sheds light on the importance of peers and the practices and environments that make a group greater than the sum of its... View Details
Keywords: Talent and Talent Management; Interactive Communication; Experience and Expertise; Decision Making; Training; Design; Compensation and Benefits; Knowledge Acquisition; Knowledge Sharing; Human Capital; Working Conditions; Measurement and Metrics; Outcome or Result; Performance; Performance Improvement; Research; Sales; Salesforce Management; Motivation and Incentives; Telecommunications Industry; Utah; United States
Stanton, Christopher, Richard Saouma, and Olivia Hull. "Clear Link Technologies, LLC: Driving Sales with Peer Effects." Harvard Business School Case 819-072, April 2019. (Revised January 2025.)
- April 2019 (Revised December 2019)
- Case
Exporting Livability: Investing in New Urban Centers
By: John D. Macomber and Essie Alamsyah
Can Singapore urban design, policy continuity, and system of laws be exported outside of Singapore to accelerate the effective development of new urban agglomerations? Nina Yang, CEO of Sustainable Urban Development at Ascendas-Singbridge, a large real estate company... View Details
Keywords: Urban Development; Projects; Design; City; Business and Government Relations; Expansion; Real Estate Industry; China; Singapore
Macomber, John D., and Essie Alamsyah. "Exporting Livability: Investing in New Urban Centers." Harvard Business School Case 219-072, April 2019. (Revised December 2019.)
- March 2019
- Case
Dabur India: Growing Professional Management from Family Roots
By: Suraj Srinivasan, Namrata Arora and Jonah Goldberg
The case opens in December of 2018, with Sunil Duggal, the CEO of Dabur India (a multinational consumer goods conglomerate with a focus in Ayurvedic products) contemplating who should succeed him at the head of the company. The new CEO will have been the first since... View Details
Keywords: Family Business; Management Succession; Multinational Firms and Management; Business Growth and Maturation
Srinivasan, Suraj, Namrata Arora, and Jonah Goldberg. "Dabur India: Growing Professional Management from Family Roots." Harvard Business School Case 119-089, March 2019.
- December 2018
- Case
Corporate Transformation at Merck KGaA, Darmstadt, Germany
By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
Fuller, Joseph B., Amy C. Edmondson, Daniela Beyersdorfer, and Tonia Labruyere. "Corporate Transformation at Merck KGaA, Darmstadt, Germany." Harvard Business School Case 319-072, December 2018.
- August 2018 (Revised February 2019)
- Case
Alvogen: Scaling Entrepreneurship
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Keywords: Pharmaceutical Companies; Scaling; Generic Drugs; Entrepreneurship; Leadership; Pharmaceutical Industry; Asia; Europe; United States; Iceland
Isenberg, Daniel, William R. Kerr, and Alexis Brownell. "Alvogen: Scaling Entrepreneurship." Harvard Business School Case 819-038, August 2018. (Revised February 2019.)
- February 2018 (Revised April 2018)
- Case
Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise
By: Michael Chu, William C. Kirby, Nancy Hua Dai and Yuanzhuo Wang
This case tells the story of how Wang Minghui, Chairman of Yunnan Baiyao Group since 1999, transformed a single-product traditional Chinese medicine (TCM) state-owned enterprise (SOE) into a major diversified consumer health player in China's highly competitive... View Details
Keywords: State-owned Enterprise (SOE); Traditional Chinese Medicine; Yunnan; Yunnan Baiyao; Consumer Health; Enterprise Transformation; Transformation; Health; Business History; State Ownership; Private Ownership; Business Strategy; Commercialization; Competition; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; China
Chu, Michael, William C. Kirby, Nancy Hua Dai, and Yuanzhuo Wang. "Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise." Harvard Business School Case 318-078, February 2018. (Revised April 2018.)
- February 2018 (Revised July 2025)
- Case
Hikma Pharmaceuticals Governance Journey
By: Lynn Paine, Suraj Srinivasan and Gamze Yucaoglu
The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns expressed by proxy advisors and some... View Details
Keywords: Boards Of Directors; Pharmaceuticals; Remuneration; Shareholder Engagement; Corporate Governance; Governing and Advisory Boards; Business and Shareholder Relations; Executive Compensation; Business Growth and Maturation; Emerging Markets; Private Sector; For-Profit Firms; Pharmaceutical Industry; Jordan
Paine, Lynn, Suraj Srinivasan, and Gamze Yucaoglu. "Hikma Pharmaceuticals Governance Journey." Harvard Business School Case 318-108, February 2018. (Revised July 2025.)
- January 2018
- Supplement
BeiGene Supplemental PowerPoint
By: Willy C. Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details
- December 2017
- Case
Charity or Bribery?
By: Eugene Soltes and Brian Tilley
Filip Kowalski, a senior manager at the pharmaceutical company Healthgen, leads sales for the firm’s Polish division. While pitching Healthgen’s products, he develops a relationship with a director of a regional health fund who also runs a private foundation. After a... View Details
Keywords: Bribery; Crime and Corruption; Law; Ethics; Philanthropy and Charitable Giving; United States; Europe
Soltes, Eugene, and Brian Tilley. "Charity or Bribery?" Harvard Business School Case 118-052, December 2017.
- December 2017 (Revised January 2018)
- Case
Alltech
By: David E. Bell and Natalie Kindred
Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech... View Details
Keywords: Alltech; United States; Agribusiness; Agriculture; Animal; Animal Agriculture; Animal Feed; Livestock; Family Business; Vertical Integration; Strategy; Growth; Feed Additives; Feed Supplements; Kentucky; Growth Strategy; Family Businesses; Animal-Based Agribusiness; Acquisition; Business Growth and Maturation; Business Model; Change Management; Trends; Governance; Entrepreneurship; Growth and Development; Intellectual Property; Leadership; Management; Markets; Organizational Culture; Private Ownership; Science; Quality; Risk and Uncertainty; Research; Sales; Pharmaceutical Industry; Pharmaceutical Industry; United States; Kentucky; Brazil; China
Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details
Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Pharmaceutical Industry; United States; United Kingdom; Australia; Germany; Europe
Krieger, Joshua Lev, Tom Nicholas, and Matthew Preble. "The 'Wonder Drug' That Killed Babies." Harvard Business School Case 818-044, November 2017.
- September 2017 (Revised June 2019)
- Case
Dianrong: Marketplace Lending, Blockchain, and 'The New Finance' in China
By: Christopher J. Malloy, Lauren H. Cohen and Anthony K. Woo
This case examines the strategic positioning of Dianrong, one of the largest online peer-to-peer (P2P) lending platforms in China, in its attempt to become a foundational player in the expansion of the FinTech sector in Asia. Dianrong had recently announced the... View Details
Keywords: Financing and Loans; Internet and the Web; Supply Chain; Finance; Innovation and Invention; Competition; Product Positioning; Strategy; Financial Services Industry; China
Malloy, Christopher J., Lauren H. Cohen, and Anthony K. Woo. "Dianrong: Marketplace Lending, Blockchain, and 'The New Finance' in China." Harvard Business School Case 218-043, September 2017. (Revised June 2019.)
- September–October 2017
- Article
GE's Global Growth Experiment: The Company Pushed Cross-Business Collaboration
By: Ranjay Gulati
Like many other companies, GE under Immelt had to figure out how to balance serving local needs with the economies of worldwide scale. Harvard Business School’s Ranjay Gulati looks at how it tackled the challenge. He identifies several important takeaways for other... View Details
Gulati, Ranjay. "GE's Global Growth Experiment: The Company Pushed Cross-Business Collaboration." Harvard Business Review 95, no. 5 (September–October 2017): 52–53.
- 2017
- Book
The Language of Global Success: How a Common Tongue Transforms Multinational Organizations
By: Tsedal Neeley
For nearly three decades, English has been the lingua franca of cross-border organizations, yet studies on corporate language strategies and their importance for globalization have been scarce. In The Language of Global Success, Tsedal Neeley provides an... View Details
Keywords: Communication; Residency; Corporate Strategy; Globalized Firms and Management; Cross-Cultural and Cross-Border Issues; Brazil; France; Germany; Indonesia; Japan; Taiwan; Thailand; United States
Neeley, Tsedal. The Language of Global Success: How a Common Tongue Transforms Multinational Organizations. Princeton, NJ: Princeton University Press, 2017.
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details
Keywords: Health Care and Treatment; Product Launch; Product Positioning; Marketing Strategy; Adoption; Pharmaceutical Industry
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.)
- June 2017
- Supplement
Transformation at Eli Lilly & Co. (B)
By: William R. Kerr and Alexis Brownell
Keywords: Eli Lilly; Pharmaceutical Companies; Restructuring; Organizational Change and Adaptation; Pharmaceutical Industry; Indiana; Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (B)." Harvard Business School Supplement 817-136, June 2017.